Find Your Medication |
Find Your Medication |
New study suggests Tamoxifen treatment should be extended to 10 years
Those individuals who buy Tamoxifen to treat and prevent the onset of breast cancer following primary treatment know that it is widely considered to be a blockbuster drug that offers protection against recurrence of the disease.
Those individuals who buy Tamoxifen to treat and prevent the onset of breast cancer following primary treatment know that it is widely considered to be a blockbuster drug that offers protection against recurrence of the disease. ER-positive breast cancer treatment Research on the appropriation of Tamoxifen over a decade was conducted by Christina Davies, M.D., a coordinator in the Clinical Trial Service Unit at the University of Oxford, and funded by various cancer research institutions. Published in the Lancet journal, the international study, titled Adjuvant Tamoxifen - Longer Against Shorter (ATLAS), was also presented at the 2012 San Antonio Breast Cancer Symposium. "ATLAS showed that protection against breast cancer recurrence and death is greater with 10 years than with five years of Tamoxifen use," explained Davies. "Women and their doctors should be aware of this evidence when deciding how long to continue Tamoxifen, or any other endocrine treatment." How Tamoxifen works Davies and the team of researchers surveyed 6,846 women with ER-positive breast cancer from the years 1996 to 2005. All the participants had been using Tamoxifen for the standard five years. Over the course of the study, participants were randomly assigned to either stop their medication after five years or to continue taking the drug. After the follow up, the researchers noted that, compared to the participants who stopped, those women who continued treatment had their recurrence rates lowered by 25 percent, while mortality rates were reduced by 29 percent. "We already knew that five years of Tamoxifen reduces breast cancer mortality in this late period by almost a third in comparison with no Tamoxifen," said Davies. "We now know that 10 years of Tamoxifen is even better, approximately halving breast cancer mortality during the second decade after diagnosis." |
See also ...
IMPORTANT DISCLOSURE: All medical content and news articles on this website is supplied by an independent third party company. While the information can be useful, this website relies on others for its creation and cannot guarantee the accuracy, medical efficacy, or reliability of the information provided. In all circumstances, you should always seek the advice of your physician and/or other qualified health professional(s) for drug, medical condition, or treatment advice. This website does not provide any medical advice. The content provided on this website is not a substitute for professional medical advice, diagnosis or treatment. |